Compare TRST & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRST | OMER |
|---|---|---|
| Founded | 1902 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 858.9M | 844.6M |
| IPO Year | 1994 | 2008 |
| Metric | TRST | OMER |
|---|---|---|
| Price | $58.93 | $17.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 122.2K | ★ 1.5M |
| Earning Date | 04-21-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.25% | N/A |
| EPS Growth | 26.46 | ★ 98.15 |
| EPS | ★ 1.89 | 0.77 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $233.22 |
| P/E Ratio | $30.93 | ★ $23.74 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $34.31 | $3.94 |
| 52 Week High | $59.10 | $19.65 |
| Indicator | TRST | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 62.35 | 51.82 |
| Support Level | $55.04 | $9.40 |
| Resistance Level | $58.98 | $17.65 |
| Average True Range (ATR) | 1.07 | 0.79 |
| MACD | 0.10 | -0.39 |
| Stochastic Oscillator | 86.55 | 1.79 |
Trustco Bank Corp N Y is a savings and loan holding company. The core part of a business consists of accepting deposits and making loans and investments. It offers a range of both personal and business banking services. The company's product includes savings accounts; retirement accounts; money market account; mortgages; building loans; auto loans and others. The company derives revenue from the business of Banking. TrustCo lends in the geographic territory of its branch locations in New York, Florida, Massachusetts, New Jersey, and Vermont.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.